Abstract
Overview
Introduction
After the launch of Trexima in 2007, triptan genericization coupled with a
weak late-stage pipeline will result in a major shift in market dynamics, and
will result in the migraine market value decreasing to $3.2 billion in 2015.
The market remains receptive to superior prophylactics however, with
innovation being essential for the progression of the acute market,
post-triptan era.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
migraine
- Overview of drugs in preregistration, Phase III, II and I; with analysis
of key companies involved in the R&D pipeline
- Detailed profiles of key compounds in development for use in migraine,
with forecasts of drug revenues to 2015
- Discussion of GSK and Pozen' s strategies and insight from key industry
opinion leaders
Report Highlights
Due to Imitrex' s commercial success, GSK is the current migraine market
leader. Trexima, co-developed by GSK and Pozen represents GSK' s product line
extension for its migraine franchise, but approval delays and the impending US
sumatriptan patent expiry will limit its success.
The next big thing in the prophylactic market will be the label expansion of
Allergan' s Botox and Ipsen' s Dysport. Seven major market Botox and Dysport
combined sales for migraine are forecast to grow to over $170m in 2015.
The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP
antagonists, amongst others in early stage clinical trials, indicate companies
are developing innovative drugs for the post triptan future. With all
identified to play a role in the biological mechanisms of migraine, there
holds great potential in such novel drug targets.
Reasons to Purchase
- Understand unmet needs in the migraine market based on key opinion leader
comments
- Benchmark key late-stage migraine compounds against current market leaders
- Assess the combined US, Japan, five major EU sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
